OPRX - OptimizeRx Corp Stock Price, Fair Value and News

9.16USD+0.22 (+2.46%)Market Closed

Market Summary

USD9.16+0.22

Market Closed

2.46%

OPRX Stock Price

View Fullscreen

OPRX RSI Chart

OPRX Valuation

Market Cap

162.6M

Price/Earnings (Trailing)

-9.25

Price/Sales (Trailing)

2.27

EV/EBITDA

-20.79

Price/Free Cashflow

-22.19

OPRX Price/Sales (Trailing)

OPRX Profitability

Operating Margin

59.98%

EBT Margin

-19.23%

Return on Equity

-13.88%

Return on Assets

-9.58%

Free Cashflow Yield

-4.51%

OPRX Fundamentals

OPRX Revenue

Revenue (TTM)

71.5M

Rev. Growth (Yr)

44.34%

Rev. Growth (Qtr)

73.71%

OPRX Earnings

Earnings (TTM)

-17.6M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-44.54%

Breaking Down OPRX Revenue

Last 7 days

-10.2%

Last 30 days

-22.1%

Last 90 days

-40.0%

Trailing 12 Months

-42.8%

How does OPRX drawdown profile look like?

OPRX Financial Health

Current Ratio

3.04

Debt/Equity

0.3

Debt/Cashflow

-0.19

OPRX Investor Care

Buy Backs (1Y)

0.81%

Diluted EPS (TTM)

-1.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	61.7M	61.6M	62.8M	71.5M
2022	63.8M	64.1M	63.1M	62.5M
2021	47.0M	51.8M	57.4M	61.3M
2020	27.0M	28.8M	34.3M	43.3M
2019	22.3M	24.2M	23.8M	24.6M
2018	14.1M	16.3M	18.6M	21.2M
2017	8.1M	9.1M	10.4M	12.1M
2016	7.5M	7.7M	7.5M	7.8M
2015	6.7M	7.0M	7.2M	7.2M
2014	5.3M	5.6M	6.2M	6.5M
2013	2.3M	2.9M	3.7M	4.7M
2012	1.0M	1.4M	1.6M	2.0M
2011	331.2K	591.3K	851.4K	1.1M
2010	0	0	0	71.1K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of OptimizeRx Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	febbo william j	acquired	-	-	60,000	ceo
Mar 01, 2024	odence-ford marion	acquired	-	-	771	general counsel and cco
Mar 01, 2024	silvestro stephen l	sold (taxes)	-10,654	15.95	-668	chief commercial officer
Mar 01, 2024	odence-ford marion	sold (taxes)	-4,274	15.95	-268	general counsel and cco
Mar 01, 2024	silvestro stephen l	acquired	-	-	1,927	chief commercial officer
Feb 11, 2024	odence-ford marion	sold (taxes)	-21,330	15.39	-1,386	general counsel and cco
Feb 11, 2024	odence-ford marion	acquired	-	-	4,000	general counsel and cco
Jan 09, 2024	febbo william j	sold (taxes)	-38,213	13.25	-2,884	ceo
Jan 09, 2024	odence-ford marion	sold	-60,750	15.1877	-4,000	general counsel and cco
Jan 09, 2024	febbo william j	acquired	-	-	9,628	ceo

Which funds bought or sold OPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.2	-27,000	7,000	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	17.26	-21,758	4,882,870	0.28%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	59,802	131,051	-%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	-26.00	146	-%
Apr 15, 2024	Legato Capital Management LLC	new	-	416,939	416,939	0.05%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	-216	1,215	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.86	6,888,220	14,610,500	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	716	716	-%
Mar 05, 2024	GREENWOOD CAPITAL ASSOCIATES LLC	added	217	1,296,930	1,564,800	0.10%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-39.73	37,483	382,534	-%

Are Funds Buying or Selling OPRX?

Are funds buying OPRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPRX

No. of Funds

Unveiling OptimizeRx Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	9.52%	1,728,430	SC 13G
Feb 13, 2024	vanguard group inc	5.62%	1,021,002	SC 13G/A
Jan 29, 2024	blackrock inc.	6.3%	1,134,954	SC 13G/A
Dec 29, 2023	divisadero street capital management, lp	5.2%	949,550	SC 13G
Nov 28, 2023	weintraub michael	7.6%	1,384,467	SC 13G
Jun 09, 2023	first light asset management, llc	10.28%	1,760,596	SC 13G
Apr 06, 2023	blackrock inc.	6.1%	1,041,738	SC 13G/A
Feb 09, 2023	vanguard group inc	6.48%	1,111,411	SC 13G/A
Jan 23, 2023	blackrock inc.	15.8%	2,714,190	SC 13G/A
Feb 11, 2022	blair william & co/il	4.1%	730,674	SC 13G/A

Recent SEC filings of OptimizeRx Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	4/A	Insider Trading
Apr 22, 2024	4/A	Insider Trading
Apr 18, 2024	8-K	Current Report
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	10-K	Annual Report
Apr 02, 2024	8-K	Current Report
Mar 28, 2024	NT 10-K	NT 10-K
Mar 11, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to OptimizeRx Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	449.3B	371.6B	-0.74%	-0.51%	20.08	1.21	14.64%	11.24%
CI	103.0B	195.3B	0.26%	37.72%	19.17	0.53	8.17%	-20.79%
CVS	85.3B	357.8B	-12.72%	-6.73%	10.21	0.24	10.95%	93.52%
HCA	84.4B	65.0B	-3.19%	11.59%	16.11	1.3	7.86%	-7.11%
CNC	40.8B	154.0B	-1.43%	12.08%	15.09	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-0.12%	51.97%	16.83	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-8.62%	17.22%	16.03	0.81	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-4.84%	8.83%	34.2	4.12	6.06%	9.17%
ACHC	6.5B	2.9B	-7.52%	-4.24%	-301.31	2.23	12.20%	-107.93%
AMN	2.2B	3.8B	-10.62%	-35.16%	10.28	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.65%	-0.29%	33.83	1.48	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.44%	-16.43%	24.79	1.46	11.31%	35.83%
BKD	1.3B	3.0B	7.61%	59.68%	-6.76	0.42	6.74%	20.73%
BEAT	53.7M	-	-3.27%	-3.72%	-3.67	-	-	-12.94%
AMS	19.0M	21.3M	13.26%	5.28%	35.63	0.89	8.00%	-62.25%

OptimizeRx Corp News

Latest updates

OptimizeRx Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	73.7%	28,368,946	16,331,484	13,818,166	13,002,910	19,654,457	15,085,504	13,978,665	13,731,530	20,312,797	16,124,951	13,625,639	11,229,211	16,426,301	10,519,191	8,783,230	7,584,602	7,379,782	5,002,767	7,006,291	5,209,434	6,579,269
Cost Of Revenue	61.2%	10,527,640	6,531,183	5,993,145	5,569,621	7,200,029	5,664,733	4,988,716	5,629,858	7,920,985	7,047,832	5,580,964	5,104,603	7,822,280	4,504,844	3,639,016	3,241,763	2,906,933	1,981,143	2,687,143	1,583,480	2,485,856
Gross Profit	82.0%	17,841,306	9,800,301	7,825,021	7,433,289	12,454,428	9,420,771	8,989,949	8,101,672	12,391,813	9,077,119	8,044,675	6,124,608	8,604,021	6,014,347	5,144,214	4,342,839	4,472,849	3,021,624	4,319,148	3,625,954	4,093,413
Operating Expenses	115.3%	28,744,479	13,353,789	12,706,889	14,496,475	13,318,776	13,177,530	12,898,479	11,862,773	11,770,733	9,038,929	7,704,536	6,762,916	7,247,553	6,191,069	6,200,027	6,602,091	6,791,312	5,008,934	3,839,105	3,493,789	4,218,860
S&GA Expenses	-100.0%	-	12,887,083	12,242,128	14,032,542	-2,883,591	12,661,703	12,320,362	11,391,233	18,911,453	3,411,602	2,900,702	2,474,946	-	-	-	-	-	-	-	-	-
EBITDA Margin	27.0%	-0.14	-0.19	-0.20	-0.20	-0.15	-0.13	-0.08	-0.01	0.04	0.06	0.06	0.03	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-163	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-2,865,298	-4,161,449	-6,397,714	-325,836	-3,466,792	-3,884,714	-3,761,098	623,462	39,894	352,100	-637,377	1,357,166	-282,894	-1,077,468	-2,203,931	-2,882,740	-1,570,942	406,617	6,529	-109,914
EBT Margin	12.2%	-0.19	-0.22	-0.23	-0.23	-0.18	-0.17	-0.11	-0.04	0.01	0.02	0.02	-0.01	-	-	-	-	-	-	-	-	-
Net Income	-44.5%	-4,141,405	-2,865,298	-4,161,449	-6,397,714	-325,836	-3,466,792	-3,884,714	-3,761,098	623,462	39,894	352,100	-637,377	1,357,166	-282,894	-1,077,468	-2,203,931	-1,984,780	-1,570,942	406,617	6,529	-109,914
Net Income Margin	-12.2%	-0.25	-0.22	-0.23	-0.23	-0.18	-0.17	-0.11	-0.04	0.01	0.02	0.02	-0.01	-	-	-	-	-	-	-	-	-
Free Cashflow	-535.1%	-6,262,524	1,439,343	-2,388,135	-114,910	2,787,146	3,438,890	281,273	4,065,764	-1,372,300	186,017	166,121	1,645,879	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	48.0%	183	124	121	132	135	136	147	138	141	135	132	128	60.00	55.00	56.00	56.00	57.00	49.00	50.00	25.00	25.00
Current Assets	-37.8%	54.00	87.00	85.00	96.00	99.00	99.00	110	113	115	108	105	101	33.00	27.00	28.00	27.00	27.00	38.00	39.00	15.00	16.00
Cash Equivalents	39.6%	14.00	10.00	10.00	16.00	18.00	41.00	87.00	89.00	85.00	85.00	84.00	82.00	11.00	12.00	14.00	15.00	19.00	30.00	31.00	10.00	9.00
Net PPE	0.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	245.6%	78.00	23.00	23.00	23.00	23.00	23.00	23.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	4.00	4.00	4.00	4.00
Liabilities	626.4%	57.00	8.00	6.00	8.00	9.00	6.00	7.00	7.00	10.00	8.00	7.00	6.00	10.00	8.00	13.00	13.00	12.00	7.00	8.00	6.00	7.00
Current Liabilities	132.2%	18.00	8.00	6.00	8.00	8.00	6.00	6.00	7.00	9.00	8.00	7.00	5.00	10.00	8.00	12.00	9.00	6.00	5.00	6.00	4.00	4.00
Long Term Debt	-	38.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	9.0%	127	116	116	124	126	130	141	131	131	127	125	122	50.00	47.00	44.00	44.00	45.00	41.00	42.00	19.00	18.00
Retained Earnings	-6.9%	-64.26	-60.12	-57.25	-53.09	-46.69	-46.37	-42.90	-39.01	-35.25	-35.88	-35.92	-36.27	-35.63	-36.99	-36.71	-35.63	-33.42	-31.44	-29.87	-30.28	-30.28
Additional Paid-In Capital	8.3%	191	176	173	177	173	176	184	170	167	163	161	158	86.00	84.00	80.00	79.00	78.00	73.00	72.00	50.00	49.00
Shares Outstanding	-6.9%	17.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	17.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	235	-	-	-	487	-	-	-	1,030	-	-	-	185	-	-	-	222	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-524.9%	-6,257	1,473	-2,368	-86.33	2,803	3,462	308	4,080	-1,334	205	190	1,666	-2,592	-106	128	-3,738	-1,499	-969	-81.77	890	933
Share Based Compensation	-18.1%	2,627	3,206	3,503	4,381	4,269	4,277	4,025	3,174	3,067	1,008	897	582	1,106	631	681	755	852	470	408	530	1,278
Cashflow From Investing	-2474.4%	-26,001	-1,009	3,223	-1,548	-18,484	-37,505	-2,120	-65.75	-99.02	-166	-135	-84.56	-79.47	-20.26	-9.06	-15.94	-9,520	-13.72	-1,033	-13.85	-5,607
Cashflow From Financing	10456.7%	36,189	-349	-7,490	-129	-7,439	-12,020	251	258	1,059	1,095	1,591	70,181	1,156	-1,954	-1,214	112	113	206	21,518	344	65.00
Buy Backs	-	-	-	7,522	-	7,463	12,241	321	-	-	-	-	-	-	-	-	-	-	-	-	-	-

OPRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenue	$ 71,521,506	$ 62,450,156
Cost of revenues, exclusive of depreciation and amortization presented separately below	28,621,589	23,483,336
Gross margin	42,899,917	38,966,820
Operating Expenses
Stock-based compensation	13,717,333	15,745,822
Loss on disposal of a business	2,142,319
Impairment charges	6,737,580
Depreciation and amortization	2,401,628	2,022,029
Other sales, general and administrative expenses	44,302,771	33,489,707
Total operating expenses	69,301,631	51,257,558
Loss from operations	(26,401,714)	(12,290,738)
Other income (expense)
Interest expense	(1,453,764)
Other income	500,001
Interest income	2,191,689	852,298
Total other income (expense), net	1,237,926	852,298
Loss before provision for income taxes	(25,163,788)	(11,438,440)
Income tax benefit	7,597,922
Net loss	$ (17,565,866)	$ (11,438,440)
Weighted average number of shares outstanding – basic (in Shares)	17,124,801	17,783,992
Weighted average number of shares outstanding – diluted (in Shares)	17,124,801	17,783,992
Loss per share – basic (in Dollars per share)	$ (1.03)	$ (0.64)
Loss per share – diluted (in Dollars per share)	$ (1.03)	$ (0.64)

OPRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 13,852,456	$ 18,208,685
Short-term investments		55,931,821
Accounts receivable, net of allowance for credit losses of $239,172 and $352,043 at December 31, 2023 and 2022, respectively	36,253,214	22,155,301
Taxes receivable	1,035,754
Prepaid expenses and other	3,189,468	2,280,828
Total Current Assets	54,330,892	98,576,635
Property and equipment, net	149,407	137,448
Other Assets
Goodwill	78,357,074	22,673,820
Patent rights, net	6,184,742	1,940,178
Technology assets, net	9,012,756	7,702,895
Tradename and customer relationships, net	34,198,084	3,379,838
Operating lease right-of-use assets	572,895	235,320
Security deposits and other assets	568,048	5,051
Total Other Assets	128,893,599	35,937,102
TOTAL ASSETS	183,373,898	134,651,185
Current Liabilities
Current portion of long-term debt	2,000,000
Accounts payable – trade	2,227,177	1,549,979
Accrued expenses	7,754,781	2,601,246
Revenue share payable	5,505,701	3,990,440
Current portion of lease liabilities	221,625	89,902
Deferred revenue	171,841	164,309
Total Current Liabilities	17,881,125	8,395,876
Non-current Liabilities
Long-term debt, net	34,230,737
Lease liabilities, net of current portion	371,438	144,532
Deferred tax liabilities, net	4,337,424
Total Liabilities	56,820,724	8,540,408
Commitments and contingencies (See Note 16)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2023 and 2022, respectively
Common stock, $0.001 par value, 166,666,667 shares authorized, 19,899,679 and 18,288,571 shares issued at December 31, 2023 and 2022, respectively	19,899	18,289
Treasury stock, $0.001 par value,1,741,397 and 1,214,398 purchased at December 31, 2023 and 2022, respectively	(1,741)	(1,214)
Additional paid-in-capital	190,792,980	172,785,800
Accumulated deficit	(64,257,964)	(46,692,098)
Total Stockholders’ Equity	126,553,174	126,110,777
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 183,373,898	$ 134,651,185

About OptimizeRx Corp

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

CEO	Mr. William J. Febbo
WEBSITE	optimizerx.com
INDUSTRY	Healthcare Plans
EMPLOYEES	109

OptimizeRx Corp Frequently Asked Questions

What is the ticker symbol for OptimizeRx Corp? What does OPRX stand for in stocks?

OPRX is the stock ticker symbol of OptimizeRx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OptimizeRx Corp (OPRX)?

As of Tue Apr 23 2024, market cap of OptimizeRx Corp is 162.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPRX stock?

You can check OPRX's fair value in chart for subscribers.

What is the fair value of OPRX stock?

You can check OPRX's fair value in chart for subscribers. The fair value of OptimizeRx Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OptimizeRx Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OptimizeRx Corp a good stock to buy?

The fair value guage provides a quick view whether OPRX is over valued or under valued. Whether OptimizeRx Corp is cheap or expensive depends on the assumptions which impact OptimizeRx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPRX.

What is OptimizeRx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, OPRX's PE ratio (Price to Earnings) is -9.25 and Price to Sales (PS) ratio is 2.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on OptimizeRx Corp's stock?

In the past 10 years, OptimizeRx Corp has provided 0.242 (multiply by 100 for percentage) rate of return.